A simplified method for cryopreservation of peripheral blood stem cells at -80 degrees C without rate-controlled freezing - PubMed (original) (raw)

Affiliations

PMID: 1721856

A simplified method for cryopreservation of peripheral blood stem cells at -80 degrees C without rate-controlled freezing

S Makino et al. Bone Marrow Transplant. 1991 Oct.

Abstract

A simplified method was established for cryopreservation of peripheral blood stem cells (PBSCs) using hydroxyethyl starch (HES) and dimethylsulfoxide (DMSO) as a cryoprotective agent at -80 degrees C without rate-controlled freezing. The data indicate that a cryoprotective solution consisting of 6% HES and 5% DMSO produced the highest recovery rates for nucleated cells (92.0 +/- 3.5%), CFU-GM (73.8 +/- 4.1%) and BFU-E (82.2 +/- 6.9%), and the highest trypan blue viability (88.4 +/- 3.6%). For long-term cryopreservation of PBSCs, CFU-GM recovery rates remained almost unchanged during 5-18 months; the mean CFU-GM recovery rate after 18 months of cryopreservation was 70 +/- 11%. When large-scale samples of PBSCs in 100-ml freezing bags were cryopreserved for clinical use, cell and CFU-GM recoveries were similar. Using this method, 10 patients with hematological malignancy received PBSC transplants after marrow-ablative chemotherapy. All demonstrated early engraftment; seven are now alive in unmaintained complete remission for 3.5-15 months after PBSC transplant. This simple and inexpensive method will be useful for the wider application of PBSC transplant as a therapeutic alternative in the treatment of malignant diseases.

PubMed Disclaimer

Comment in

Storage of PBSC at -80 degrees C.
Watts MJ, Sullivan AM, Ings SJ, Barlow M, Devereux S, Goldstone AH, Linch DC. Watts MJ, et al. Bone Marrow Transplant. 1998 Jan;21(1):111-2. doi: 10.1038/sj.bmt.1701050. Bone Marrow Transplant. 1998. PMID: 9486506 No abstract available.

Cited by

Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04).
Murayama T, Fukuda T, Okumura H, Sunami K, Sawazaki A, Maeda Y, Tsurumi H, Uike N, Hidaka T, Takatsuka Y, Eto T, Tsuda H, Fujisaki T, Miyamoto T, Tsuneyoshi N, Iyama S, Nagafuji K, Harada M. Murayama T, et al. Int J Hematol. 2016 Jun;103(6):676-85. doi: 10.1007/s12185-016-1976-4. Epub 2016 Mar 21. Int J Hematol. 2016. PMID: 27084252 Clinical Trial.
Essential requirements for setting up a stem cell processing laboratory.
Leemhuis T, Padley D, Keever-Taylor C, Niederwieser D, Teshima T, Lanza F, Chabannon C, Szabolcs P, Bazarbachi A, Koh MB; Graft Processing Subcommittee of the Worldwide Network for Blood and Bone Marrow Transplantation (WBMT). Leemhuis T, et al. Bone Marrow Transplant. 2014 Aug;49(8):1098-105. doi: 10.1038/bmt.2014.104. Epub 2014 Jun 16. Bone Marrow Transplant. 2014. PMID: 24933209
No Detectable Alteration of Inorganic Allogeneic Bone Matrix Colonizing Mesenchymal Cells: A Step Towards Personalized Bone Grafts.
Erivan R, Samper N, Villatte G, Boisgard S, Descamps S, Berger M. Erivan R, et al. J Bone Metab. 2021 May;28(2):161-169. doi: 10.11005/jbm.2021.28.2.161. Epub 2021 May 31. J Bone Metab. 2021. PMID: 34130368 Free PMC article.
Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission.
Eto T, Takase K, Miyamoto T, Ohno Y, Kamimura T, Nagafuji K, Takamatsu Y, Teshima T, Gondo H, Taniguchi S, Akashi K, Harada M. Eto T, et al. Int J Hematol. 2013 Aug;98(2):186-96. doi: 10.1007/s12185-013-1378-9. Epub 2013 Jun 11. Int J Hematol. 2013. PMID: 23754766

A simplified method for cryopreservation of peripheral blood stem cells at -80 degrees C without rate-controlled freezing - PubMed (original) (raw)